Drug Profile
Research programme: pharmacological chaperones - Cantabio Pharmaceuticals
Alternative Names: CB 102Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Gardedam Therapeutics; Purdue University
- Developer Cantabio Pharmaceuticals
- Class Small molecules
- Mechanism of Action Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 29 Aug 2023 Preclinical development is ongoing in USA (Cantabio pipeline, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 11 Jul 2016 Cantabio Pharmaceuticals signs a cooperation agreement with Purdue Research Foundation for studies on pharmacological chaperones for Parkinson's disease and other neurodegenerative disorders